All In Biotech

Drug Trial Radar · NCT02369978

CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY)

Cardiovascular Health Investigation and Collaboration From Countries of America to Assess the Markers and Outcomes of Chagas Disease (CHICAMOCHA-3) - EQUITY (Equivalence of Usual Interventions for Trypanosomiasis)

Last checked: Nov 20, 2026Latest source record: Jul 21, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

500

Planned (sponsor's estimate)

Start

Aug 2015

Primary completion

Aug 2018

Study completion Feb 2019

Sponsor

Lead sponsor
Universidad Autónoma de BucaramangaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Fundación Cardioinfantil Instituto de Cardiología; Instituto Nacional de Salud, Colombia; Instituto Nacional de Parasitologia Dr. Mario Fatala Chaben
First posted
Feb 24, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, blind, parallel-group trial will evaluate the efficacy and safety of Nifurtimox (NFX) and Benznidazole (BZN), the two usual interventions to treat the parasite Trypanosoma cruzi. The investigators will test whether NFX is an effective trypanocidal agent (by comparison with placebo) and equivalent to BZN (as active comparator) in terms of both parasite-related and safety outcomes. Individuals found seropositive and without clinical signs of dilated cardiomyopathy will receive either of the active treatments or matching placebo. Participants allocated to NFX or BZN will receive either a 60-day (full-dose) or a 120-day (half-dose) active treatment, whereas the control group will receive placebo for 120 days. There will be thus four arms of active treatment (NFX60, NFX120, BZN60 and BZN120), and a fifth control arm receiving placebo (1:1:1:1:1 allocation ratio) where every participant in the trial will take 120 days of study drug (the groups receiving full-dose will complete a 120-day masked treatment with placebo). The study plans to enroll 500 participants from Colombia (in two different geographical areas) and Argentina, in order to explore regional differences in the treatment effects.

Conditions

  • Chagas Disease

Interventions

  • NifurtimoxDrug

    Full dose: 8 mg/Kg/day, assuming an average weight of 60 Kg: 240 mg B.I.D Half-dose: 120 mg B.I.D

  • BenznidazoleDrug

    Full dose: 5 mg/Kg/day, assuming an average weight of 60 Kg: 150 mg B.I.D Half dose: 75 mg B.I.D

  • PlaceboDrug

    Two capsules of matching placebo (contaning Magnesium stearate and cellulose) B.I.D

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Quantitative Polymerase Chain Reaction (qPCR) for Trypanosoma cruziTime frame: 12 - 18 months after starting therapy

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fundación Oftalmológica de Santander - Clínica Ardila Lulle (FOSCAL)

    Bucaramanga, Santander Department, Colombia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.